Philip A. Downing

Philip Downing brings to Inotiv over 22 years of pharmaceutical experience in drug discovery, toxicology/non-clinical, and clinical research to his role as senior vice president of nonclinical services. Trained as a bioanalytical chemist, Downing joined Inotiv’s legacy company, BASi, as an analytical chemist in 1997, rapidly progressing through leadership positions of increasing responsibility as director of analytical services, general manager, and senior director of preclinical services, before taking on his current executive role.

Previously, Downing worked at GFi Pharmaceuticals (now the clinical division within Covance Labs) as an analytical scientist and radiation safety officer designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. He is a member of the Society of Toxicology, the American College of Toxicology, and the American Chemical Society.

Back to Team